A podcast delves into the deployment of Bayesian Health's AI platform in clinical settings, focusing on clinician adoption, patient outcomes, and comparing TREWS with other decision support tools. Topics include the importance of early detection and treatment of sepsis, developing the TRUZ AI model, gaining clinician trust in deploying CDS tools, and the power of AI platforms in healthcare.
TRUCE platform focuses on early sepsis detection to improve patient outcomes.
TRUCE platform demonstrated high sensitivity levels and reduced antibiotic administration time.
Deep dives
Bayesian Health's TRUCE Platform for Early Sepsis Detection
The introduction of Bayesian Health's TRUCE platform, aimed at early sepsis identification, is imperative due to sepsis being a significant cause of hospital mortalities. The platform focuses on timely detection to enhance patient outcomes, highlighting the critical need for prompt sepsis management. Dr. Suchi Saria's research emphasizes the importance of leveraging existing data effectively to identify potential sepsis cases early, illustrating the substantial lead time benefits observed with TRUCE's deployment.
Prospective Studies on Clinical Adoption and Patient Outcomes
In two prospective studies, TRUCE demonstrated high sensitivity levels of 82%, confirming one in three sepsis alerts by physicians, a crucial achievement in avoiding false alerts that hamper adoption. Additionally, the platform facilitated a significant lead time of 5.7 hours earlier detection compared to standard practices, enabling timelier administration of life-saving treatments like antibiotics. Furthermore, providers engaging with TRUCE led to a notable 1.85-hour reduction in antibiotic administration time, showcasing tangible benefits in patient care.
Technology and Clinician Adoption Dynamics
Bayesian Health's innovative approach of integrating AI into early detection systems like TRUCE presents a shift from traditional, less adaptive models. By addressing the complexity and diversity of patient data and clinical settings, the platform adapts to various scenarios, enhancing its efficacy and usability. Clinicians' positive reception and high adoption rates demonstrate the value of intelligent augmentations like TRUCE in improving healthcare outcomes and highlights the importance of collaborating technologies within established clinical workflows.
On this episode, we discuss three recent papers out in Nature Medicine this week, all examining the deployment of Bayesian Health's AI platform in a clinical setting: Two prospective studies focused on clinician adoption and patient outcomes, and one interview-based study focused on clinical experiences with Bayesian’s AI platform, TREWS.
First, we get into detail about the design and results of the prospective studies, then we talk about TREWS in context with other clinical decision support tools. Finally, we talk about clinicians’ attitudes toward adoption.
Featuring Dr. Suchi Saria, PhD, and the CEO of Bayesian Health; Dr. Neri Cohen, MD, PhD, as well as a collaborator with Bayesian Health; and Dr. Vineeta Agarwala, MD, PhD, and a16z general partner. Hosted by Olivia Webb.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode